Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sanofi-Aventis Licenses Anti-Angiogenesis Technology from SIBS

publication date: Dec 6, 2010
Sanofi-Aventis has in-licensed a technology patent from Shanghai Institutes for Biological Sciences (SIBS) that may lead to an anti-angiogenesis cancer drug. The patent covers SIBS’s discovery of the importance of the Slit-Robo signaling path for tumor vasculature and tumor growth. The total deal is worth $60 million, according to Data Monitor, which includes an upfront payment, milestones and royalties on sales. More details....

Stock Symbol: (NYSE: SNY)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital